Travere Therapeutics, a company specializing in rare kidney diseases, recently received FDA approval for its first therapy targeting FSGS, a severe rare kidney condition. The company is also advancing a Phase III trial for a treatment of classical homocystinuria. This approval marks a significant milestone, offering new hope for patients with FSGS and reinforcing Travere's commitment to innovative rare disease treatments.
Axsome Therapeutics showcased new clinical data on SYMBRAVO, their migraine treatment combining meloxicam and rizatriptan, at the American Headache Society's 68th Annual Scientific Meeting. The presentations covered efficacy, safety, and comparative ...
Clean Energy Fuels Corp. has launched its eighth dairy renewable natural gas (RNG) facility at East Valley Cattle in Jerome, Idaho, one of North America's largest dairies. The facility processes over 5 million gallons of manure daily using advanced t...
Broadcom's CEO confirmed a bold forecast of over $100 billion in AI semiconductor revenue for fiscal year 2027, following a 180% revenue jump to $56 billion in 2026. The company has extended customer commitments through 2028, reflecting strong demand...
Auddia Inc. has started developing the McCarthy Finney Operating System (MCFN-OS), an AI-native, Web3-enabled platform designed to automate workflows and support multiple subsidiaries with agentic AI and blockchain trust. The first production module ...
US Signal is significantly expanding its Aurora, Illinois data center to increase power capacity and resiliency, supporting growing enterprise needs for hybrid cloud, AI infrastructure, and data protection. The multi-phase upgrade will more than doub...
